Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599024 | 0.89 | CNR2 (0.61) | CNR2HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4598647 | 0.81 | CNR2 (0.58) | CNR2HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL5525884 | 0.75 | ALDH1A1 (0.56) | CNR2TSHRALDH1A1KMT2A | |
| SCHEMBL12190754 | 0.74 | TP53 (0.74) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL30302445 | 0.73 | TP53 (0.77) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL30371836 | 0.73 | TP53 (0.77) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL30475759 | 0.73 | TP53 (0.77) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL15558380 | 0.73 | TP53 (0.77) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL16917421 | 0.73 | TP53 (0.67) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL2847927 | 0.73 | TP53 (0.77) | TP53TSHRPLA2G4BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910309-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016012-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027199-A1 | Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation | BACE1, BACE2, APP | CNR2 778/4885TP53 3689/4885TSHR 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.